LETTER TO THE EDITOR
|Year : 2021 | Volume
| Issue : 6 | Page : 935-936
Impact of Levodopa in Lung Functions in Patients with Parkinson's Disease
Mahmood D Al-Mendalawi
Professor in Paediatrics and Child Health, Consultant Paediatrician, Department of Paediatrics, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq
|Date of Submission||12-Jun-2020|
|Date of Acceptance||03-Jul-2020|
|Date of Web Publication||11-Apr-2021|
Mahmood D Al-Mendalawi
P.O.Box 55302, Baghdad Post Office, Baghdad
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Al-Mendalawi MD. Impact of Levodopa in Lung Functions in Patients with Parkinson's Disease. Ann Indian Acad Neurol 2021;24:935-6
I read the interesting study by Tandon et al. published in May-June 2020 issue of the Annals of Indian Academy of Neurology. They found that 39% of Indian patients with Parkinson's disease had restrictive ventilatory dysfunctions prior to morning administration of dopamine. Of these, 40% developed improvement after administration of levodopa. The following methodological limitation deserves consideration. In the study methodology, Tandon et al. mentioned that they utilized European Respiratory Society (ERS)/European Community for Coal and Steel (ECCS) as a predictive reference (PR) for spirometry with the adjustment of normogram values for gender, height, and weight to evaluate the recordings of the various elements of pulmonary function tests (PFT). The impact of this limitation could be disclosed in dual aspects. On the one hand, ERS/ECCS PR of spirometry was released more than two decades ago and primarily derived for Caucasian populations. On the other hand, normal lung function is influenced by nutritional, physiological, genetic, psychological, socioeconomic, environmental, and ethnic determinants. Based on these determinants and to avoid misinterpretation of PFT, many populations- specific PR of spirometry have been developed to be applied in clinical and nonclinical work. Interestingly, India is among pioneer countries that have already determined pulmonary function components in normal healthy people and derived reliable PR of spirometry. I wonder why Tandon et al. employed ERS/ECCS PR of spirometry in the methodology rather than national standard. I, therefore, assume that the above-mentioned methodological limitation together with the few study limitations addressed by Tandon et al. could importantly question the accuracy of the study results.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Tandon M, Ahmad FM, Narayanan S, Mohan C, Yadav S. Impact of levodopa in lung functions in patients with Parkinson disease. Ann Indian Acad Neurol 2020;23:338-41. [Full text]
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993;6(Suppl 16):S5-40.
Rivero-Yeverino D. Spirometry: Basic concepts. Rev Alerg Mex 2019;66:76-84.
Rufino R, Costa CH, Lopes AJ, Maiworm AI, Maynard K, Silva LM, et al
. Spirometry reference values in the Brazilian population. Braz J Med Biol Res 2017;50:e5700.
Nayak PK, Satpathy S, Manjareeka M, Samanta P, Mishra J, Pradhan BB. Normal spirometric standards in young adult Indian population. J Basic Clin Physiol Pharmacol 2015;26:321-5.